Wegovy’s Real-World Cardiovascular Results Could Be a Game Changer for Novo Nordisk (CPSE:NOVO B)

• At the recent European Society of Cardiology Congress in Madrid, Novo Nordisk presented results from the STEER real-world study showing that Wegovy® markedly reduced major cardiovascular events compared to tirzepatide among patients with obesity and established cardiovascular disease, but without diabetes.
• This new evidence, based on real-world patient data, strengthens Wegovy®’s position as a potentially differentiated treatment in the growing obesity and cardiometabolic space.
• We'll examine how these stronger cardiovascular outcomes for Wegovy® could shift Novo Nordisk’s investment narrative and long-term growth outlook.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Novo Nordisk Investment Narrative Recap

To see value in Novo Nordisk, you need to believe in sustained global expansion and deepening demand for GLP-1 therapies in obesity and cardiometabolic disease, fueled by ongoing real-world evidence of clinical benefit. The recent STEER study's results could amplify interest in Wegovy®’s cardiovascular benefits, reinforcing momentum behind global adoption, though rising price pressures and unauthorized drug compounding in the US market remain major short-term headwinds. For now, the update is supportive for the leading near-term catalyst, but does not remove the main risks.

Beyond the clinical results, Novo Nordisk’s new multi-year research partnership with Replicate Bioscience stands out, aiming to power future therapeutics for obesity and cardiometabolic diseases. While the STEER data bolster confidence in current products, progress through collaborations like this could shape new catalysts in an increasingly competitive space.

In contrast, investors should also be aware of the risk that persistent and unlawful mass compounding of GLP-1 products in the US could undermine...

Read the full narrative on Novo Nordisk (it's free!)

Novo Nordisk's narrative projects DKK396.7 billion revenue and DKK142.5 billion earnings by 2028. This requires 8.3% yearly revenue growth and an increase of DKK31.4 billion in earnings from DKK111.1 billion today.

Uncover how Novo Nordisk's forecasts yield a DKK465.30 fair value, a 30% upside to its current price.

Exploring Other Perspectives

122 individual fair value estimates from the Simply Wall St Community range widely from DKK377.67 to DKK1,308.61. This variety of views appears while price pressures and compounding risks weigh on the company’s growth outlook, inviting you to compare alternative opinions.

Explore 122 other fair value estimates on Novo Nordisk - why the stock might be worth over 3x more than the current price!

Build Your Own Novo Nordisk Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Novo Nordisk research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Novo Nordisk research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novo Nordisk's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Find companies with promising cash flow potential yet trading below their fair value.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com